<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976959</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2021000121</org_study_id>
    <nct_id>NCT04976959</nct_id>
  </id_info>
  <brief_title>High Fiber in Parkinson's Disease</brief_title>
  <official_title>High Fiber in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to determine the effects of a high-fiber nutritional&#xD;
      supplement (HFS) on the bacteria, viruses, and fungi that live in different regions of the&#xD;
      body in those with Parkinson's disease (PD). We will compare the bacteria, viruses, and fungi&#xD;
      of those with PD to those without PD (healthy controls). We will also examine the effects of&#xD;
      transplanting stool from humans into laboratory mice with or without Parkinson-like pathology&#xD;
      to understand how the microbiome influences the brains of animals. We can use this&#xD;
      information to get a better understanding of how changing the microbiome might help humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in microbiome composition</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parkinson's patients who will receive a high fiber supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no supplement will be given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Fiber supplement</intervention_name>
    <description>The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.</description>
    <arm_group_label>Parkinson's patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's disease patients who are untreated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Occupation expected to change the microbiome (e.g. sanitation worker)&#xD;
&#xD;
          -  Treatment with medications that may induce parkinsonism (e.g. metoclopramide, typical&#xD;
             or atypical antipsychotic agents)&#xD;
&#xD;
          -  Treatment within 12 weeks with oral or intravenous antibiotics&#xD;
&#xD;
          -  Known diagnosis of inflammatory bowel disease&#xD;
&#xD;
          -  Symptomatic organic gastrointestinal (GI) disease (other than hemorrhoids and hiatal&#xD;
             hernia) or abdominal surgeries for symptomatic gastrointestinal disease such as bowel&#xD;
             resection, diverticular surgery, colostomy; subjects with a history of an appendectomy&#xD;
             or gallbladder removal for non-cancerous disease more than 5 years prior to&#xD;
             presentation are allowed.&#xD;
&#xD;
          -  Symptomatic functional GI disease that significantly impairs intestinal motility such&#xD;
             as scleroderma or use of GI motility drugs&#xD;
&#xD;
          -  Acute illness requiring immediate hospitalization&#xD;
&#xD;
          -  Pre-existent conditions as below:&#xD;
&#xD;
          -  Liver disease (cirrhosis or persistently abnormal AST or ALT that are 2X&gt; normal);&#xD;
&#xD;
          -  Kidney disease (creatinine&gt;2.0 mg/dL);&#xD;
&#xD;
          -  Uncontrolled psychiatric illness;&#xD;
&#xD;
          -  Clinically important lung disease or heart failure;&#xD;
&#xD;
          -  HIV disease;&#xD;
&#xD;
          -  Alcoholism, unreliable drinking history; or consumption of alcohol more than 3 times a&#xD;
             week or binge drinking or drinking more than or equal to 3 drinks per occasion;&#xD;
&#xD;
          -  Transplant recipients;&#xD;
&#xD;
          -  Diabetes;&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Clinically significant dehydration or clinically detectable ascites or peripheral&#xD;
             edema or cardiac failure&#xD;
&#xD;
          -  Presence of short bowel syndrome or severe malnutrition with ideal body weight &lt; or =&#xD;
             90%&#xD;
&#xD;
          -  Use of immunosuppressive medications in 3 months prior to enrollment&#xD;
&#xD;
          -  Anti-inflammatory medication use within 3 weeks of enrollment.&#xD;
&#xD;
          -  Chronic use of diuretics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Pal, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Pal, MD, MS</last_name>
    <phone>7322357733</phone>
    <email>gian.pal@rutgers.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rutgers-RWJ University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Pal</last_name>
      <phone>732-235-7733</phone>
      <email>gian.pal@rutgers.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Gian Dev Pal, MD, MS</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

